Relief Therapeutics Holding AG Asset Resilience Ratio

Latest as of December 2023: 0.01%

Relief Therapeutics Holding AG asset resilience ratio. Relief Therapeutics Holding AG (RLF) has an Asset Resilience Ratio of 0.01% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Relief Therapeutics Holding AG defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CHF9.00K
≈ $11.38K USD Cash + Short-term Investments

Total Assets

CHF76.39 Million
≈ $96.58 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Relief Therapeutics Holding AG (2006–2023)

Asset resilience ratio of Relief Therapeutics Holding AG from 2006 to 2023. This chart shows how Relief Therapeutics Holding AG's Asset Resilience Ratio has changed over time. Read Relief Therapeutics Holding AG (RLF) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Relief Therapeutics Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RLF asset base.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF0.00 0%
Short-term Investments CHF9.00K 0.01%
Total Liquid Assets CHF9.00K 0.01%

Asset Resilience Insights

  • Limited Liquidity: Relief Therapeutics Holding AG maintains only 0.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Relief Therapeutics Holding AG Industry Peers by Asset Resilience Ratio

Compare Relief Therapeutics Holding AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Relief Therapeutics Holding AG Asset Resilience Ratio by Year (2006–2023)

Relief Therapeutics Holding AG asset resilience ratio by year from 2006 to 2023. The table below shows the annual Asset Resilience Ratio data for Relief Therapeutics Holding AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.01% CHF9.00K
≈ $11.38K
CHF76.39 Million
≈ $96.58 Million
0.00pp
2022-12-31 0.01% CHF28.00K
≈ $35.40K
CHF188.80 Million
≈ $238.69 Million
--
2021-12-31 0.00% CHF0.00
≈ $0.00
CHF251.62 Million
≈ $318.11 Million
--
2020-12-31 0.24% CHF185.00K
≈ $233.89K
CHF78.05 Million
≈ $98.67 Million
+0.18pp
2013-12-31 0.06% CHF25.73K
≈ $32.54K
CHF45.98 Million
≈ $58.13 Million
-18.38pp
2006-12-31 18.43% CHF14.15 Million
≈ $17.89 Million
CHF76.76 Million
≈ $97.05 Million
--
pp = percentage points

About Relief Therapeutics Holding AG

SW:RLF Switzerland Biotechnology
Market Cap
$45.93 Million
CHF36.33 Million CHF
Market Cap Rank
#22861 Global
#204 in Switzerland
Share Price
CHF2.89
Change (1 day)
+0.87%
52-Week Range
CHF2.56 - CHF2.99
All Time High
CHF280.00
About

Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more